Cutler Group’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-14,400
| Closed | -$232K | – | 5644 |
|
|
2022
Q3 | $232K | Buy |
14,400
+3,800
| +36% | +$157K | 0.02% | 896 |
|
|
2022
Q2 | $78K | Sell |
10,600
-13,300
| -56% | -$293K | 0.01% | 1610 |
|
|
2022
Q1 | $87K | Sell |
23,900
-42,000
| -64% | -$1.18M | ﹤0.01% | 1806 |
|
|
2021
Q4 | $354K | Sell |
65,900
-8,500
| -11% | -$298K | 0.01% | 934 |
|
|
2021
Q3 | $331K | Buy |
74,400
+16,200
| +28% | +$252K | 0.01% | 1024 |
|
|
2021
Q2 | $129K | Buy |
58,200
+57,900
| +19,300% | +$1.43M | 0.01% | 1660 |
|
|
2021
Q1 | $1K | Sell |
300
-3,400
| -92% | -$205K | ﹤0.01% | 5483 |
|
|
2020
Q4 | $17K | Sell |
3,700
-2,200
| -37% | -$126K | ﹤0.01% | 2813 |
|
|
2020
Q3 | $31K | Buy |
5,900
+2,200
| +59% | +$118K | ﹤0.01% | 2144 |
|
|
2020
Q2 | $28K | Sell |
3,700
-2,300
| -38% | -$125K | ﹤0.01% | 2160 |
|
|
2020
Q1 | $29K | Buy |
+6,000
| New | +$255K | ﹤0.01% | 2085 |
|
|
2018
Q4 | – | Sell |
-1,000
| Closed | -$2K | – | 4820 |
|
|
2018
Q3 | $2K | Buy |
+1,000
| New | +$12K | ﹤0.01% | 3637 |
|
|
2016
Q3 | – | Sell |
-9,300
| Closed | -$5K | – | 7597 |
|
|
2016
Q2 | $5K | Buy |
+9,300
| New | +$34.9K | ﹤0.01% | 5008 |
|
|
2016
Q1 | – | Sell |
-6,400
| Closed | -$6K | – | 7422 |
|
|
2015
Q4 | $6K | Buy |
+6,400
| New | +$45.3K | ﹤0.01% | 4763 |
|
Other funds holding CCXI
Cutler Group's CCXI Position: Q4 2022 in Review
Cutler Group sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 8,000 shares — an estimated $413K sold.
Cutler Group first reported a position in CCXI in Q4 2015 and held it in 23 quarters. The position peaked at $635K in Q1 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Cutler Group reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Cutler Group sold 8,000 ChemoCentryx, Inc. shares in Q4 2022, an estimated $413K.
- Cutler Group first reported a position in ChemoCentryx, Inc. in Q4 2015 and held it in 23 quarters.
- Cutler Group's ChemoCentryx, Inc. position peaked at $635K in Q1 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.